Drug Interactions Database

6278 interactions from BNF 85 - Check your medicines

Source: BNF 85
Severity: All 6278 Severe 944 Moderate 1418 Unknown 3916
antimalarials penicillamine

increases risk of haematologicaltoxicity

Severe Theoretical
antimalarials remdesivir

decreases effects

Severe Theoretical
antipsychotics,secondgeneration(amisulpride,olanzapine, paliperidone,quetiapine,risperidone dopaminereceptoragonists

decreases effects

Severe Theoretical
ataluren intravenousaminoglycosides

increases risk of nephrotoxicity

Severe Study
benperidol dopaminereceptoragonists

decreases effects

Severe Theoretical
beta 2agonists linezolid

increases risk of elevatedbloodpressure

Severe Theoretical
betablockers,selective aminophylline

increases risk of bronchospasm

Severe Theoretical
betablockers,selective theophylline

increases risk of bronchospasm

Severe Theoretical
bismuthsubsalicylate aspirin

increases risk of adverseeffects

Severe Theoretical
bisphosphonates parathyroidhormone

decreases effects

Severe Study
bosentan anti-androgens

decreases exposure

Severe Theoretical
bosentan antifungals,azoles

decreases exposure

Severe Theoretical
bosentan antipsychotics,secondgeneration

decreases exposure

Severe Theoretical
bosentan cariprazine

decreases exposure

Severe Theoretical
bosentan ciclosporinandciclosporinmoderatelyincreasestheexposuretobosentan

decreases exposure

Severe Study
bosentan darolutamide

decreases exposure

Severe Theoretical
bosentan elbasvir

decreases exposure

Severe Study
bosentan elvitegravir

decreases concentration

Severe Theoretical
bosentan finerenone

decreases exposure

Severe Study
bosentan glibenclamide

increases risk of hepatotoxicity

Severe Study
bosentan grazoprevir

decreases exposure

Severe Study
bosentan isavuconazole

decreases exposure

Severe Theoretical
bosentan larotrectinib

decreases exposure

Severe Study
bosentan mineralocorticoidreceptorantagonists

decreases exposure

Severe Study
bosentan mobocertinib

decreases exposure

Severe Study
bosentan paclitaxel

decreases exposure

Severe Study
bosentan sirolimusandsirolimuspotentiallyincreasestheconcentrationofbosentan

decreases concentration

Severe Theoretical
bosentan sulfonylureas

increases risk of hepatotoxicity

Severe Study
bosentan tacrolimusandtacrolimuspotentiallyincreasestheconcentrationofbosentan

decreases concentration

Severe Theoretical
bosentan temsirolimus

decreases concentration

Severe Theoretical
bosentan voxilaprevir

decreases concentration

Severe Theoretical
bosentan zanubrutinib

decreases exposure

Severe Theoretical
brentuximabvedotin bleomycin

increases risk of pulmonarytoxicity

Severe Study
brigatinib alfentanil

decreases concentration

Severe Theoretical
brigatinib fentanyl

decreases concentration

Severe Theoretical
brigatinib opioids

decreases concentration

Severe Theoretical
brigatinib sirolimus

decreases concentration

Severe Theoretical
brigatinib tacrolimus

decreases concentration

Severe Theoretical
bupropion moclobemide

increases risk of severehypertension

Severe Theoretical
buspirone linezolid

increases risk of elevatedbloodpressure

Severe Theoretical
calciumchannelblockers fidaxomicin

increases exposure

Severe Study
carbamazepine antipsychotics,secondgeneration

increases risk of myelosuppression

Severe Anecdotal
carbamazepine berotralstat

decreases concentration

Severe Theoretical
carbamazepine clozapine

increases risk of myelosuppression

Severe Anecdotal
carbamazepine dabigatran

decreases exposure

Severe Study
carbamazepine ledipasvir

decreases exposure

Severe Study
carbamazepine sofosbuvir

decreases exposure

Severe Study
carbamazepine thrombininhibitors

decreases exposure

Severe Study
carbimazole metyrapone

decreases effects

Severe Theoretical
ceritinib alfentanil

increases exposure

Severe Theoretical
Prev 1 2 3 4 ... 126 Next
6278 interactions
Important: This database uses data from the British National Formulary (BNF 85). It is for informational purposes only and is not a substitute for professional medical advice.